Isarna receives orphan drug designation for ISTH0036 in Europe

Isarna Therapeutics announced that the European Medicines Agency has granted orphan drug designation for ISTH0036 for prevention of scarring after glaucoma filtration surgery. A phase 1 trial of the drug began in April for patients with advanced stage glaucoma who have undergone glaucoma filtration surgery.

Full Story →